Containing -c(=x)x-, Wherein The X's Are The Same Or Diverse Chalcogens Patents (Class 534/16)
  • Patent number: 10214632
    Abstract: The present invention relates to a novel and economical process for modification of acid scavenger to be used not only for neutralizing the effect of catalyst residue but as well as crystallinity modifier in polyolefins. More particularly, the present invention discloses a process for modification of acid scavenger to be used as dual functional additive as acid scavenger as well as crystallinity modifier in polyolefins, said process comprising treating an acid scavenger with an organic dibasic acid to obtain a modified acid scavenger, wherein the acid scavenger is calcium aluminum hydroxy carbonate having chemical formula Ca4Al2(OH)12CO3.nH2O, where n=4-5.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 26, 2019
    Assignee: INDIAN OIL CORPORATION LIMITED
    Inventors: Jatinder Singh Dhaliwal, Vishal Goel, Shiva Naresh, Priyanka Luthra, Sameeksha Raizada, Gurpreet Singh Kapur, Shashi Kant
  • Patent number: 9408848
    Abstract: Disclosed are molecules and their synthesis. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: August 9, 2016
    Assignee: Georgetown University
    Inventors: Venkata Mahidhar Yenugonda, Milton L. Brown
  • Patent number: 9163155
    Abstract: Luminescent lanthanide complex and inks containing the complex as well as its method of production and article including the complex, wherein the complex includes the formula: wherein M is chosen from the alkali cations Li+, Na+, K+, Rb+ and Cs+ and mixtures thereof and is present to neutralize charge of the complex; wherein Ln is chosen from the trivalent rare-earth cations of Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, and Yb and mixtures thereof; wherein R is a C5 to C6 heteroaryl: wherein Y is an optionally substituted C3-C8 heterocycloalkyl moiety linked to R by an N atom; wherein n is an integer of 3 or 5; and wherein x is an integer of 0 or 1.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: October 20, 2015
    Assignee: SICPA HOLDING SA
    Inventors: Frédéric Thomas, Cécile Laporte
  • Patent number: 9127139
    Abstract: Process for labelling a material based on at least one organic thermoplastic or thermosetting polymer matrix comprising a step that consists in incorporating therein, by dispersion during its manufacture or its formation, at least one compound based on at least one photoluminescent rare earth in a concentration that renders this compound detectable under UV irradiation, said compound being a coordination polymer that is in the form of a crystallite obtained by reaction of at least one photoluminescent rare-earth ion with at least one unsaturated organic ligand.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: September 8, 2015
    Assignee: INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE RENNES
    Inventors: Olivier Guillou, Carole Daiguebonne, Nicolas Kerbellec
  • Publication number: 20150132229
    Abstract: The present invention describes a new class of trinuclear heavy metal complexes comprising two hexadentate azainositol tricarboxylic acid ligands, a method for their preparation and their use as X-ray contrast agents.
    Type: Application
    Filed: April 25, 2013
    Publication date: May 14, 2015
    Inventors: Markus Berger, Heribert Schmitt-Willich, Detlev Sülzle, Hubertus Pietsch, Thomas Frenzel, Gregor Jost, Kaspar Hegetschweiler, Christian Neis, Silvia Lauria
  • Patent number: 9006316
    Abstract: The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: April 14, 2015
    Assignee: King Industries, Inc.
    Inventors: Bing Hsieh, Ramanathan Ravichandran, Farouk Abi-Karam
  • Publication number: 20150087500
    Abstract: The present invention relates to a neodymium compound represented by Formula 1 and a catalyst for diene polymerization including the same.
    Type: Application
    Filed: August 18, 2014
    Publication date: March 26, 2015
    Inventors: Hyo Jin BAE, Kyoung Hwan OH, Sae Young YUN, Jeong Heon AHN, Woo Jin CHO
  • Patent number: 8987429
    Abstract: Disclosed herein is a GO-Gd-DTPA (gadolinium-diethylenetriamine pentaacetic-graphene oxide) complex, which is formed by an ester bond of graphene oxide (GO) and gadopentetic acid (Gd-DTPA). Since the GO-Gd-DTPA can stably exist in the body because it has high stability in water, it is expected that it can be effectively used as an MRI contrast agent.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 24, 2015
    Assignee: Research and Business Foundation Sungkyunkwan University
    Inventors: Hyo Young Lee, Luyang Wang
  • Publication number: 20150071863
    Abstract: The invention relates to compositions of DOTA derivative compounds, lanthanoid-DOTA derivative molecular complex, and lanthanoid-complex encapsulated solid lipid particles or capsules, and methods of making and using the compositions. The solid lipid particles or capsules contain micelle cores stabilized by a hyperbranched polymer shell based from a crosslinked DOTA derivative compound or crosslinked lanthanoid-DOTA derivative complex. These solid lipid particles or capsules can be used in various applications, such as contrast agents or drug delivery vehicles.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 12, 2015
    Inventor: Marc Anton WALTERS
  • Publication number: 20150005483
    Abstract: Disclosed herein is a GO-Gd-DTPA (gadolinum-diethylenetriamine pentaacetic-graphene oxide) complex, which is formed by an ester bond of graphene oxide (GO) and gadopentetic acid (Gd-DTPA). Since the GO-Gd-DTPA can stably exist in the body because it has high stability in water, it is expected that it can be effectively used as an MRI contrast agent.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 1, 2015
    Applicant: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
    Inventors: Hyo Young LEE, Luyang WANG
  • Publication number: 20140341806
    Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
    Type: Application
    Filed: August 5, 2014
    Publication date: November 20, 2014
    Inventors: Jeffrey P. Norenberg, Richard S. Larson
  • Patent number: 8877163
    Abstract: A cycloalkyl triamine pentacarboxylate compound coordinating to a metal ion to form a high stability metal complex in serum is provided. The metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: November 4, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Yun-Ming Wang, Chih-Wei Chiu, Gin-Chung Liu
  • Publication number: 20140302664
    Abstract: Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Applicant: PIXELLIGENT TECHNOLOGIES, LLC
    Inventors: Zehra Serpil GONEN WILLIAMS, Yijun Wang, Robert J. Wiaceck, Xia Bai, Linfeng Gou, Selina I. Thomas, Wei Xu, Jun Xu, Rakesh Patel
  • Publication number: 20140302324
    Abstract: The invention relates to a hydrophobic thermoplastic copolymer which is in particular of use for manufacturing and/or coating medical devices, in particular implantable medical devices, characterized in that it is obtained by copolymerization, and in that it comprises at least one first monomer unit and at least one second monomer unit onto which is grafted a paramagnetic-ion-chelating ligand which can complex with such a paramagnetic ion or a paramagnetic-ion-chelating ligand which is complexed with such a paramagnetic ion, wherein the second monomer unit is grafted in sufficient amount for the copolymer to be visible in magnetic resonance imaging when it is complexed with said paramagnetic ion. The invention also relates to a method for obtaining said hydrophobic thermoplastic copolymer.
    Type: Application
    Filed: December 7, 2012
    Publication date: October 9, 2014
    Applicant: Centre National de la Recherche Scientifique
    Inventors: Jean Coudane, Vincent Darcos, Sarah El Habnouni, Xavier Garric, Laurent Lemaire, Benjamin Nottelet
  • Publication number: 20140295649
    Abstract: Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 2, 2014
    Applicant: PIXELLIGENT TECHNOLOGIES, LLC
    Inventors: Zehra Serpil GONEN WILLIAMS, Yijun Wang, Robert J. Wiacek, Xia Bai, Linfeng Gou, Selina I. Thomas, Wei Xu, Jun Xu, Rakesh Patel
  • Publication number: 20140255306
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of PSMA. Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
    Type: Application
    Filed: January 10, 2014
    Publication date: September 11, 2014
    Applicant: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. BABICH, Craig ZIMMERMAN, John L. JOYAL, Genliang LU
  • Publication number: 20140228553
    Abstract: The present invention relates to organic compounds that are usable as ligands for preparing complexes of lanthanides or of certain transition metals which are water-soluble, to a method for preparing same, and also to the use thereof as a fluorescent probe.
    Type: Application
    Filed: October 11, 2012
    Publication date: August 14, 2014
    Inventors: Raymond Ziessel, Mathieu Starck, Alexandra Sutter
  • Publication number: 20140227297
    Abstract: Provided herein is technology relating to theranostic agents and particularly, but not exclusively, to compositions comprising cell-specific theranostic agents and associated methods and systems for using the cell-specific theranostic agents to treat subjects.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 14, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Sascha N. Goonewardena, Bertram Pitt, Hong Zong
  • Publication number: 20140228552
    Abstract: The present invention provides a MRI contrast enhancing agent, which comprises: a magnetic particle with a T2-reducing effect; a polymer coupled to a surface of the magnetic particle; and a T1 contrast agent coupled to the polymer.
    Type: Application
    Filed: February 8, 2013
    Publication date: August 14, 2014
    Applicant: National Cheng Kung University
    Inventor: Ping-Ching WU
  • Publication number: 20140212354
    Abstract: A method of selecting a corrosion-inhibiting substance includes selecting a corrosion-inhibiting substance to include a non-tungstate anodic corrosion inhibitor with respect to an amount of zinc in an aluminum alloy substrate that is to be coated with the corrosion-inhibiting substance.
    Type: Application
    Filed: March 31, 2014
    Publication date: July 31, 2014
    Inventors: Sarah Arsenault-Preece, James T. Beals, Mark R. Jaworowski
  • Publication number: 20140199239
    Abstract: The present disclosure provides lipid-probe compounds, and compositions comprising the compounds. A subject lipid-probe compound is useful for various imaging applications, which are also provided.
    Type: Application
    Filed: May 16, 2011
    Publication date: July 17, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Carolyn Ruth Bertozzi, Andreas Stahl, Amy Helene Henkin, Elena A. Dubikovskaya, Allison Cohen
  • Publication number: 20140187527
    Abstract: The present disclosure provides a novel class of macrocyclic compounds and their metal complexes formed with transition metal ion, lanthanide metal ions and other metal ions (e.g., Al, Ga, Y, In, Sn, Tl, Pb and Bi) and their applications in the fields of contrast agents, artificial nucleases, fluorescence probes, nuclear medicines and other biomedical applications in the therapeutics or diagnostics.
    Type: Application
    Filed: December 31, 2012
    Publication date: July 3, 2014
    Applicant: NATIONAL YANG MING UNIVERSITY
    Inventors: Cheng Allen Chang, Ren-Shyan Liu, Bhalchandra Vishnu Bhagwat
  • Publication number: 20140179015
    Abstract: The invention provides a compound of formula (I): (wherein: R1 is an optionally substituted 2-(1-azathiaxanthone); each —R2 is independently of the formula —CH2—C(?O)—R4, wherein R4 is an amino acid or a salt thereof, attached to the remainder of R2 through the nitrogen atom of the amino group; and R3 is hydrogen or a C1-6 alkyl group); or (wherein: R1 is an optionally substituted 2-(1-azaxanthone); each R2 is independently an optionally substituted glutaric or succinic acid, or a salt or ester thereof; and R3 is hydrogen or a C1-6 alkyl group).
    Type: Application
    Filed: December 16, 2013
    Publication date: June 26, 2014
    Applicant: University of Durham
    Inventors: David PARKER, Robert Pal
  • Publication number: 20140171627
    Abstract: The present invention describes multimeric multimodality probes. In particular, the present invention discloses (strept)avidin specific multimeric biotinidase resistant multimodality probes.
    Type: Application
    Filed: December 13, 2012
    Publication date: June 19, 2014
    Inventors: Kumar Ranjan Bhushan, Preeti Misra
  • Publication number: 20140154815
    Abstract: A method of changing the fluorescent properties of a complex, the method comprising: providing a first complex comprising a multidentate ligand that is coordinated to a lanthanide ion, wherein the lanthanide is selected from europium and terbium and the multidentate ligand has at least one optionally substituted phthalimide group coordinated to the lanthanide ion, contacting the complex with an aqueous liquid medium under appropriate conditions, such that at least one phthalimide group is hydrolysed to a phthalamate group, to form a second complex. Complexes and compounds are also disclosed.
    Type: Application
    Filed: April 13, 2012
    Publication date: June 5, 2014
    Applicant: LONDON METROPOLITAN UNIVERSITY
    Inventors: Sim-Wan Annie Bligh, Nicholas Paul Chatterton, Nicholas James Wardle, Jason Lee Sarris, Gaoyun Chen
  • Publication number: 20140107325
    Abstract: What is described is a process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is carried out using specifically controlled crystallization conditions. The more recent developments in the field of the gadolinium-containing MR contrast agents (EP 0448191 B1, CA Patent 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) include the MRT contrast agent gadobutrol (Gadovist® 1.0) which has been approved for a relatively long time in Europe and more recently also in the USA under the name Gadavist®.
    Type: Application
    Filed: April 17, 2012
    Publication date: April 17, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Publication number: 20140093664
    Abstract: Luminescent lanthanide complex and inks containing the complex as well as its method of production and article including the complex, wherein the complex includes the formula: wherein M is chosen from the alkali cations Li+, Na+, K+, Rb+ and Cs+ and mixtures thereof and is present to neutralize charge of the complex; wherein Ln is chosen from the trivalent rare-earth cations of Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, and Yb and mixtures thereof; wherein R is a C5 to C6 heteroaryl: wherein Y is an optionally substituted C3-C8 heterocycloalkyl moiety linked to R by an N atom; wherein n is an integer of 3 or 5; and wherein x is an integer of 0 or 1.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 3, 2014
    Applicant: SICPA HOLDING SA
    Inventors: Frédéric THOMAS, Cécile LAPORTE
  • Publication number: 20140080163
    Abstract: A molecular probe for the luminescent detection of nucleotides (e.g., adenosine nucleotides) is presented. In certain embodiments, the probe can readily distinguish between the three adenosine nucleotides in buffered aqueous conditions at neutral pH, a need for the direct monitoring of enzymatic reactions converting ATP to ADP or AMP. The probe is most efficient under millimolar concentrations of ATP, which are relevant to intracellular conditions. In preferred embodiments, the long luminescence lifetime of the probe readily enables time-gating experiments.
    Type: Application
    Filed: September 10, 2013
    Publication date: March 20, 2014
    Inventor: Valerie Christine Pierre
  • Publication number: 20140081009
    Abstract: This invention includes agents and compositions having MRI, PET, CT, X-ray, SPECT or optical signals, and methods for their use in the determination of a target. In some cases, a MRI, PET, CT, X-ray, SPECT, optical or other signal produced by the agent or composition can be affected by the presence of the target. Examples of targets that can be determined by this invention include, but are not limited to zinc, copper, iron ions and other biological targets. Example of application for imaging in vivo includes the function of pancreas and other organs.
    Type: Application
    Filed: December 2, 2013
    Publication date: March 20, 2014
    Inventor: Luis M. De Leon-Rodriguez
  • Publication number: 20140058072
    Abstract: The present invention describes dual-modality probes. In particular, the present invention discloses fibrosis specific multimeric small-molecule peptidomimetic dual-modality MRI and optical probes.
    Type: Application
    Filed: August 27, 2012
    Publication date: February 27, 2014
    Inventors: Kumar Ranjan Bhushan, Preeti Misra
  • Publication number: 20140058073
    Abstract: The present invention provides a rare earth metal complex represented by the following formula (I).
    Type: Application
    Filed: March 12, 2012
    Publication date: February 27, 2014
    Applicant: B.R.A.H.M.S. GmbH
    Inventors: Mikio Hoshino, Toshisada Yano, Yasukazu Yamanaka
  • Publication number: 20140045323
    Abstract: Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films.
    Type: Application
    Filed: October 16, 2013
    Publication date: February 13, 2014
    Inventors: Zehra Serpil GONEN WILLIAMS, Yijun WANG, Robert J. WIACEK, Xia BAI, Linfeng GOU, Selina I. THOMAS, Wei XU, Jun XU, Rakesh PATEL
  • Patent number: 8637620
    Abstract: The invention relates to a process for preparing a polymeric material doped with metal elements, comprising a step of polymerization of at least one monomer comprising at least one ethylenic function, said monomer being complexed with a metal element. Use of the materials obtained by means of this process as catalysts, or luminescent or magnetic materials, or as elements for laser targets.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: January 28, 2014
    Assignee: Commissariat A l'Energie Atomique et aux Energies Alternatives
    Inventors: Alexia Balland Longeau, Louis Moreau, Jérôme Thibonnet, Emilie Velasquez
  • Publication number: 20140017807
    Abstract: The present application discloses a luminescent lanthanide chelate comprising one or more chromophoric moieties of the formula (I) or of the formula (III) wherein R1, R2 and R2* each independently are selected from carbon-containing substituents forming a C—O bond with the neighbouring oxygen atom, R3 and R4 each represent a bond between the chromophoric moiety and other moieties of the chelate, and Ln3+ is a lanthanide ion, as well as the corresponding luminescence lanthanide chelating ligand. The application also discloses a detectable molecule comprising a biospecific binding reactant (such as an antibody) conjugated to the luminescent lanthanide chelate as well as a method of carrying out a biospecific binding assay, the use of such a detectable molecule in a specific bioaffinity based binding assay utilizing time-resolved fluorometric determination of a specific luminescence, and a solid support material conjugated with the luminescent lanthanide chelate.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 16, 2014
    Applicant: DHR Finland OY
    Inventors: Niko Meltola, Harri Takalo, Henri Sund
  • Publication number: 20140005369
    Abstract: The present invention relates to a new uridine nucleoside-based amphiphilic gadolinium complex and a magnetic resonance imaging (MRI) contrast agent including the gadolinium complex. The MRI contrast agent has high relaxivity, high binding affinity for and stability in human serum albumin, pH response, and high liver specificity.
    Type: Application
    Filed: March 15, 2012
    Publication date: January 2, 2014
    Applicants: KOREA BASIC SCIENCE INSTITUTE, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Jong-Seung Kim, Sankarprasad Bhuniya, Sumin Lee, Kwan Soo Hong, Hyunseung Lee, Hyeyoung Moon
  • Publication number: 20130296539
    Abstract: The present invention discloses magnetic resonance compatible contrast agents for water-poor structures, such as bone and tissue calcification. In particular, the present invention discloses bisphosphonate-based magnetic resonance imaging contrast agents specific for hydroxyapatite, the calcium salt most commonly associated with malignant calcification.
    Type: Application
    Filed: May 7, 2012
    Publication date: November 7, 2013
    Inventor: Kumar Ranjan Bhushan
  • Publication number: 20130283977
    Abstract: A process for the extraction of rare earth elements, including yttrium, from a rare earth element-bearing ore or concentrate, comprising the steps of leaching the rare earth element-bearing ore or concentrate with a lixiviant of hydrochloric acid and magnesium chloride at atmospheric pressure at a temperature of from 90° C. to the boiling point of the solution and at an Eh of at least 200 mV. After a liquid/solids separation step, the solution obtained is subjected to steps for removal of iron and for recovery of rare earth elements. Alternatively, rare earth element-bearing ore or concentrate may be leached with sulphuric acid and liquid obtained subjected to extraction of iron and other impurities. Raffinate obtained may be treated with oxalic acid, the precipitate dissolved in hydrochloric acid and subjected to solvent extraction for rare earth elements or the raffinate may be subjected to solvent extraction for removal of rare earth elements and then stripped with hydrochloric acid.
    Type: Application
    Filed: April 8, 2013
    Publication date: October 31, 2013
    Inventors: Vaikuntam I. Lakshmanan, Ramamritham Sridhar, M. A. Halim
  • Publication number: 20130266886
    Abstract: Ion conductive organic-inorganic composite particles are particles that have an organic group on the surface of inorganic particles and have at least a configuration that does not allow the inorganic particles to contact with each other by steric hindrance of the organic group, the organic group containing an ion conductive group.
    Type: Application
    Filed: April 11, 2011
    Publication date: October 10, 2013
    Applicant: NITTO DENKO CORPORATION
    Inventors: Yoshiharu Hatakeyama, Hideyuki Emori, Hiroyuki Nishii, Junichi Nagase, Shusaku Shibata, Saori Fukuzaki, Tatsuki Nagatsuka, Takahiro Fukuoka
  • Publication number: 20130216478
    Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 22, 2013
    Inventor: STC.UNM
  • Publication number: 20130210165
    Abstract: The present application discloses a luminescent lanthanide chelate of formula (I) with lanthanides such as europium, as well as the corresponding luminescence lanthanide chelating ligand. The application also discloses a detectable molecule comprising a biospecific binding reactant (such as an antibody) conjugated to the luminescent lanthanide chelate as well as a method of carrying out a biospecific binding assay, the use of such a detectable molecule in a specific bioaffinity based binding assay utilizing time-resolved fluorometric determination of a specific luminescence, and a solid support material conjugated with the luminescent lanthanide chelate.
    Type: Application
    Filed: August 17, 2012
    Publication date: August 15, 2013
    Applicant: DHR Finland Oy
    Inventors: Niko Meltola, Harri Takalo
  • Publication number: 20130195768
    Abstract: The present invention relates to the use of non-equivalent mobile protons belonging to NMR distinguishable steroisomers of a CEST agent in a ratiometric based CEST imaging procedure and to Lanthanide (III) complex compounds displaying at least two NMR-distinguishable steroisomers in solution useful as concentration independent CEST responsive agents.
    Type: Application
    Filed: November 4, 2011
    Publication date: August 1, 2013
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Silvio Aime, Daniela Delli Castelli, Franco Fedeli, Dario Livio Longo, Enzo Terreno, Fulvio Uggeri
  • Publication number: 20130183771
    Abstract: The present application discloses a luminescent lanthanide chelate comprising one or more chromophoric moieties of the formula (I) or of the formula (III) wherein R1, R2 and R2* each independently are selected from carbon-containing substituents forming a C—O bond with the neighbouring oxygen atom, R3 and R4 each represent a bond between the chromophoric moiety and other moieties of the chelate, and Ln3+ is a lanthanide ion, as well as the corresponding luminescence lanthanide chelating ligand. The application also discloses a detectable molecule comprising a biospecific binding reactant (such as an antibody) conjugated to the luminescent lanthanide chelate as well as a method of carrying out a biospecific binding assay, the use of such a detectable molecule in a specific bioaffinity based binding assay utilizing time-resolved fluorometric determination of a specific luminescence, and a solid support material conjugated with the luminescent lanthanide chelate.
    Type: Application
    Filed: December 21, 2012
    Publication date: July 18, 2013
    Applicant: DHR Finland OY
    Inventor: DHR Finland OY
  • Publication number: 20130158241
    Abstract: The invention relates to a method for producing crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid of the formula I by saponifying 3,6,9-triaza-3,6,9-tris(tert-butoxycarbonylmethyl)-4-(4-ethoxybenzyl)-undecanedioic acid di-tert-butyl ester of the formula II in an aqueous alkali metal hydroxide solution and using 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid of the formula I for producing the gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid [(Gd-EOB-DTPA)=Primovist®].
    Type: Application
    Filed: June 6, 2011
    Publication date: June 20, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Publication number: 20130079503
    Abstract: Disclosed herein is a GO-Gd-DTPA (gadolinum-diethylenetriamine pentaacetic-graphene oxide) complex, which is formed by an ester bond of graphene oxide (GO) and gadopentetic acid (Gd-DTPA). Since the GO-Gd-DTPA can stably exist in the body because it has high stability in water, it is expected that it can be effectively used as an MRI contrast agent.
    Type: Application
    Filed: September 10, 2012
    Publication date: March 28, 2013
    Applicant: Research & Business Foundation Sungkyunkwan University
    Inventors: Hyo Young LEE, Luyang WANG
  • Publication number: 20120329174
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.
    Type: Application
    Filed: April 30, 2012
    Publication date: December 27, 2012
    Applicant: The Regents of the University of California
    Inventors: Kenneth N. RAYMOND, Tood M. CORNEILLIE, Jide XU
  • Patent number: 8323621
    Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: December 4, 2012
    Assignees: Vanderbilt University, Texas Tech University System
    Inventors: Darryl J. Bornhop, H. Charles Manning, Timothy Goebel
  • Patent number: 8293133
    Abstract: Crystals of [VOBDC](H2BDC)0.71 were synthesized hydrothemally. The guest acid molecules were removed by heating in air to give high quality single crystals of VOBDC. VOBDC was observed to show crystal-to-crystal transformations on absorption of the guest molecules aniline, thiophene and acetone from the liquid phase. Accurate structural data of the guest molecules and framework deformations were obtained from single crystal X-ray data. VOBDC was also shown to absorb selectively thiophene and dimethyl sulphide from methane.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: October 23, 2012
    Assignee: The University of Houston System
    Inventors: Allan J. Jacobson, Xiqu Wang, Lumei Liu
  • Publication number: 20120258043
    Abstract: Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl LeX, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.
    Type: Application
    Filed: April 26, 2012
    Publication date: October 11, 2012
    Applicant: BRACCO SUISSE S.A.
    Inventors: Ramachandran RANGANATHAN, Kondareddiar RAMALINGAM, Radhakrishna PILLAI, Edmund R. MARINELLI, Rolf E. SWENSON
  • Patent number: RE44338
    Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 2, 2013
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky
  • Patent number: RE44354
    Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 9, 2013
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky